Celcuity (NASDAQ:CELC) given new $150.00 price target at Stifel Nicolaus. August 14, 2026 Key points. * Stifel Nicolaus lowered Celcuity's price target to $150 from $175 while maintaining a "buy" rating, implying 73.21% upside from the previous close. * Analyst sentiment remains broadly positive: 10 analysts rate the stock a Buy and one rates it Sell, producing a consensus "Moderate Buy" rating and a $153.64 average target. * Celcuity shares fell 6.0% to open at $86.60 after the company reported a quarterly EPS loss of $1.44, missing estimates, while revenue of $0.09 million came in well below the $4.42 million consensus. * Interested in Celcuity? Here are five stocks we like better. Celcuity (NASDAQ:CELC - Get Free Report) had its target price decreased by equities researchers at Stifel Nicolaus from $175.00 to $150.00 in a report released on Friday,Benzinga reports. The firm currently has a "buy" rating on the stock. Stifel Nicolaus' price objective indicates a potential upside of 73.21% from the stock's previous close. A number of other research analysts also recently issued reports on CELC. Needham & Company LLC dropped their price target on shares of Celcuity from $157.00 to $140.00 and set a "buy" rating on the stock in a research report on Friday. Wells Fargo & Company lowered their target price on shares of Celcuity from $183.00 to $166.00 and set an "overweight" rating for the company in a research note on Wednesday, June 3rd. Leerink Partners set a $155.00 price target on shares of Celcuity in a research report on Tuesday, June 2nd. Weiss Ratings upgraded Celcuity from a "sell (e+)" rating to a "sell (d-)" rating in a report on Thursday, June 4th. Finally, Macquarie Infrastructure set a $160.00 price objective on Celcuity in a research report on Thursday, May 28th. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $153.64. Celcuity trading down 6.0%. Shares of CELC stock opened at $86.60 on Friday. The stock has a market cap of $4.22 billion, a price-to-earnings ratio of -22.21 and a beta of 0.20. The stock has a 50-day moving average of $93.81 and a 200-day moving average of $108.56. The company has a current ratio of 12.31, a quick ratio of 12.31 and a debt-to-equity ratio of 6.04. Celcuity has a 1-year low of $44.42 and a 1-year high of $151.02. Celcuity (NASDAQ:CELC - Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($1.44) EPS for the quarter, missing analysts' consensus estimates of ($1.16) by ($0.28). The company had revenue of $0.09 million during the quarter, compared to the consensus estimate of $4.42 million. On average, equities research analysts forecast that Celcuity will post -3.76 earnings per share for the current year. Institutional investors weigh in on Celcuity. Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Brandywine Managers LLC acquired a new position in shares of Celcuity during the second quarter valued at about $693,000. Nan Fung Group Holdings Ltd bought a new stake in Celcuity in the 2nd quarter valued at about $2,960,746,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Celcuity in the 2nd quarter valued at about $9,567,000. Elevation Point Wealth Partners LLC acquired a new position in Celcuity during the 2nd quarter worth approximately $216,000. Finally, Blue Owl Capital Holdings LP bought a new position in Celcuity in the second quarter worth approximately $131,000. 63.33% of the stock is owned by institutional investors. Celcuity company profile. Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors. Discover more Options profit calculator Cryptocurrency market data Celcuity's proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Celcuity, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celcuity wasn't on the list. While Celcuity currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

NASDAQ: CELC investigation alert: Kessler Topaz Meltzer & Check, LLP encourages Celcuity Inc. (NASDAQ: CELC) investors to contact the firm. Business Wire 28-Jul-2026 7:50 PM Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Celcuity Inc. ((CELC) on behalf of investors who purchased or acquired Celcuity Inc. securities and experienced significant financial losses. Celcuity Announces Unexpected Delayed Drug Launch On July 14, 2026, Celcuity Inc. issued a press release announcing that it had secured FDA approval for its breast cancer therapy Revtorpyk (gedatolisib) and "anticipates commercial launch in late Q3 2026", representing a delayed launch timeline relative to analyst expectations. Commenting on the announcement, a Stifel analyst noted that "late 3Q26 launch guidance seems somewhat extended." A Leerink analyst agreed, noting that while the "approval was largely expected... we did not anticipate [a Q3 launch date] given prior commentary on launch readiness." Celcuity's Stock Drops Over 17% Following the news of Celcuity Inc.'s delayed drug launch, the company's stock price fell over 17%. Investors who purchased Celcuity Inc. (NASDAQ:CELC) securities and experienced losses may have legal rights under the federal securities laws. CONTACT KTMC TO DISCUSS YOUR LEGAL RIGHTS: There is no cost or obligation to speak with an attorney. ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP (KTMC): Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including being recognized in Chambers & Partners USA 2026 as a Band 1 Top Firm in Securities and Class Actions, Legal 500's Tier 1 Rankings for Securities and M&A Litigation, The National Law Journal's Plaintiff's Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group's Honor Roll of Most Feared Law Firms, The Legal Intelligencer's Class Action Firm of the Year, Lawdragon's Leading Plaintiff Financial Lawyers, and Law360's Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for its clients and the classes they represent. May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes. Jonathan Naji, Esq. 280 King of Prussia Road Radnor, PA 19087 (484) 270-1453 [email protected]